US2007037222A1PendingUtilityA1
Lineage restricted glial precursors
Individually held — no corporate assignee on recordPriority: Jul 4, 1997Filed: Jul 14, 2006Published: Feb 15, 2007
Est. expiryJul 4, 2017(expired)· nominal 20-yr term from priority
A61P 25/00C12N 5/0623C12N 2501/395C12N 2506/02G01N 33/5058C12N 2501/135C12N 2510/00A61P 25/28C12N 2503/02C12N 5/0622A61K 35/12
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Glial precursor cell populations from mammalian central nervous system and embryonic stem cells has been isolated. These A2B5 + E-NCAM − glial-restricted precursor (GRP) cells are capable of differentiating into oligodendrocytes, A2B5 + process-bearing astrocytes, and A2B5 − fibroblast-like astrocytes, but not into neurons. GRP cells can be maintained by regeneration in culture. GRP cells differ from oligodendrocyte-type-2 astrocyte (0-2A) progenitor cells in growth factor requirements, morphology, and progeny. Methods of use of GRP cells are also disclosed.
Claims
exact text as granted — not AI-modified1 . An isolated population of mammalian glial-restricted precursor cells derived from mammalian embryonic stem cells, said mammalian glial-restricted precursor cells being immunonegative for PDGF-α receptor, PDGF-β receptor, and Ran-2 antigen, not labeled with R24 anti-GD3 antibody, and immunopositive for A2B5 antigen.
2 . A method for isolating a population of mammalian glial-restricted precursor cells comprising:
(a) incubating mammalian embryonic stem cells under differentiation-inducing conditions so that the cells differentiate; and (b) isolating a population of mammalian glial-restricted precursor cells by immunoselecting A2B5-immunoreactive cells from the differentiated cells.
3 . The method of claim 2 wherein immunoselecting A2B5-immunoreactive cells is performed via a procedure selected from the group consisting of specific antibody capture, fluorescence activated cell sorting, and magnetic bead capture.
4 . A population of mammalian CNS glial restricted precursor cells isolated by the method of claim 2 .
5 . The population of mammalian CNS glial restricted precursor cells of claim 3 wherein said cells are immunonegative for PDGF-α receptor, PDGF-β receptor, and Ran-2 antigen, not labeled with R24 anti-GD3 antibody, and immunopositive for A2B5 antigen.Join the waitlist — get patent alerts
Track US2007037222A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.